# BLTE catalysts: BELITE BIO, INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/blte/catalysts

> BELITE BIO, INC (BLTE) has 5 upcoming catalysts. The next is the tinlarebant PDUFA date, February 12, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BLTE?

BELITE BIO, INC (BLTE) has 5 upcoming catalysts. The next is the tinlarebant PDUFA date, February 12, 2027. Press release filed with the SEC (EX-99): "Fee Act (PDUFA) target action date of February 12, 2027" [Calendar and source filings](https://sec-api.dev/companies/blte/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125573, https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/blte/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BELITE BIO, INC |
| Ticker | BLTE (Nasdaq) |
| SEC CIK | 1889109 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/blte |

## Cash runway

Cash $352.9M as of 2025-12-31; quarterly burn $9.3M; about 114.4 months of runway at that rate (XBRL company facts, accession 0001104659-26-037374).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [Tinlarebant trial start](https://sec-api.dev/pdufa/tinlarebant) | BLTE | GA associated with dry AMD | completed | "In addition, we have initiated our Phase 3 trial named "PHOENIX" to evaluate the safety and efficacy of tinlarebant in patients with GA associated with dry AMD, and have randomized the first subject in July 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)) |
| late 2024 | [Tinlarebant interim data readout](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | scheduled | "Company expects to report interim analysis by end of 2024 or early 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465924116159/tm2427528d1_ex99-1.htm)) |
| August 4, 2025 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Stargardt Disease 1 | completed | "NCT05244304 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05244304)) |
| Q4 2025 | [BELITE BIO, INC topline data readout](https://sec-api.dev/companies/blte/catalysts) | BLTE |  | scheduled | "Trial completed, final topline data remains on track for Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465925108842/tm2530713d1_ex99-1.htm)) |
| Q4 2025 | [BELITE BIO, INC topline data readout](https://sec-api.dev/companies/blte/catalysts) | BLTE |  | scheduled | "Completed pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465925108842/tm2530713d1_ex99-1.htm)) |
| Q4 2025 | [Tinlarebant interim data readout](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | scheduled | "Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465925024128/tm258947d1_ex99-1.htm)) |
| Q2 2026 | [Tinlarebant NDA/BLA submission](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | scheduled | "Although we announced the top-line results of the Phase 3 DRAGON in December 2025 and we expect to submit an NDA to the FDA in the second quarter of 2026, the foregoing risks regarding marketing approvals remain applicable to tinlarebant." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)) |
| Aug 2026 | [Tinlarebant NDA/BLA acceptance](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | completed | "In August 2026, the FDA accepted the NDA for tinlarebant in STGD1 and granted" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm)) |
| Sep 2026 | [Tinlarebant NDA/BLA submission](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | completed | "The Company submitted a J-NDA to the Ministry of Health, Labour and Welfare (MHLW) in Japan for tinlarebant in STGD1 in September 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm)) |
| February 12, 2027 | [Tinlarebant PDUFA date](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | scheduled | "Fee Act (PDUFA) target action date of February 12, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm)) |
| Jun to Sep 2027 | [Tinlarebant topline data readout](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Geographic Atrophy | scheduled | "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949593)) |
| June 2027 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Geographic Atrophy | scheduled | "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949593)) |
| February 2028 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | STGD1; Stargardt Disease 1 | scheduled | "NCT06388083 (A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388083)) |
| Feb to May 2028 | [Tinlarebant topline data readout](https://sec-api.dev/pdufa/tinlarebant) | BLTE | STGD1; Stargardt Disease 1 | scheduled | "NCT06388083 (A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388083)) |

## Drugs

- [Tinlarebant](https://sec-api.dev/pdufa/tinlarebant): ga associated with dry amd, Stargardt Disease 1, STGD1, Geographic Atrophy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/blte/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BLTE catalysts: BELITE BIO, INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/blte/catalysts

```bibtex
@misc{secapidev_companies_blte_catalysts_20261116,
  title        = {BLTE catalysts: BELITE BIO, INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/blte/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_blte_catalysts_20261116","title":"BLTE catalysts: BELITE BIO, INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/blte/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
